How big is the Asia-Pacific Glucagon-like Peptide-1 Agonists Market?

The Asia-Pacific Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 0.9 billion in 2024 and grow at a CAGR of 5.38% to reach USD 1.17 billion by 2029. Read More

What is the current Asia-Pacific Glucagon-like Peptide-1 Agonists Market size?

In 2024, the Asia-Pacific Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 0.9 billion. Read More

Who are the key players in Asia-Pacific Glucagon-like Peptide-1 Agonists Market?

AstraZeneca, Eli Lilly and Company, Novo Nordisk A/S, Sanofi Aventis and Biocon Ltd. are the major companies operating in the Asia-Pacific Glucagon-like Peptide-1 Agonists Market. Read More

What years does this Asia-Pacific Glucagon-like Peptide-1 Agonists Market cover, and what was the market size in 2023?

In 2023, the Asia-Pacific Glucagon-like Peptide-1 Agonists Market size was estimated at USD 0.85 billion. The report covers the Asia-Pacific Glucagon-like Peptide-1 Agonists Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Glucagon-like Peptide-1 Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Asia-Pacific Glucagon-like Peptide-1 (GLP-1) AgonistsCompanies

This report lists the top Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists industry.